A Phase 1, Randomized, Placebo-Controlled, Double-Blind, Dose-Escalation Study to Evaluate Safety, Tolerability and Pharmacokinetics of Single Doses of Q203 in Normal, Healthy, Male and Female Volunteers
Overview
- Phase
- Phase 1
- Intervention
- Q203
- Conditions
- Healthy Volunteers
- Sponsor
- Qurient Co., Ltd.
- Enrollment
- 56
- Primary Endpoint
- Safety assessed through adverse events, vital signs, ECG, laboratory results, and telemetry monitoring
- Status
- Completed
- Last Updated
- 9 years ago
Overview
Brief Summary
Randomized, double-blind, placebo-controlled, dose-escalation study in healthy male and female volunteers. Subjects will be randomly assigned to 1 of 7 treatment cohorts (Cohorts 1 - 7) of 8 subjects each, to receive either Q203 or placebo (6 active treatment : 2 placebo) in a fasting state.
Dose escalation to the next cohort may be considered when at least 6 out of 8 subjects, in a cohort, completes all procedures and none of the subjects has a clinically significant adverse event (AE) that is being followed, or at the discretion of the PI if no drug-related serious adverse events (SAEs) have occurred.
A food effect cohort will be enrolled to test administration of Q203 in a fed state, at 100 mg dose level (this dose level may change based on PK analysis results). Subjects who received 100mg dose in a fasting state will return and receive the second dose, with food.
Subjects will be followed up for AEs, SAE or pregnancy for 30 days postdrug administration.
Detailed Description
Randomized, double-blind, placebo-controlled, dose-escalation study in healthy male and female volunteers. Subjects will be randomly assigned to 1 of 7 treatment cohorts (Cohorts 1 - 7) of 8 subjects each, to receive either Q203 or placebo in a fasting state. Every attempt will be made to include at least 2 females in each cohort, at least one of whom will be assigned to receive Q203. Dose escalation to the next cohort may be considered when at least 6 out of 8 subjects, in a cohort, completes all procedures and none of the subjects has a clinically significant adverse event (AE) that is being followed, or at the discretion of the PI if no drug-related SAEs have occurred. A food effect cohort will be enrolled to test administration of Q203 in a fed state, at 100 mg dose level (this dose level may change based on PK analysis results). Subjects who received 100mg dose in a fasting state will return and receive the second dose, with food. In this cohort, all eight subjects will proceed to receive either Q203 or placebo in a six to two ratio (six active treatment : 2 placebo). Every attempt will be made to include at least 2 females in this cohort, at least one of whom will be assigned to receive Q203. Subjects will be followed up for AEs, SAE or pregnancy for 30 days postdrug administration.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Able to understand and sign an informed consent form.
- •Healthy adult males and females of non-childbearing potential, ages 18 to 55 years, inclusive at the time of screening.
- •Body mass index of 18 to 32 kg/m2, inclusive, and weighing at least 50 kg.
- •Female subjects must be of non-childbearing potential (postmenopause or surgical sterilization). Postmenopausal status will be confirmed by a follicle-stimulating hormone (FSH) test at screening.
- •Male subjects must agree to use a condom with spermicide when engaging in sexual intercourse during the study period and for 30 days after study drug dosing, if they have not had a vasectomy at least 6 months before study start.
- •Male subjects must not donate sperm during the study and for 30 days after study drug dosing.
- •Able to understand and comply with all of the study requirements.
- •Able to swallow 8 tablets in succession.
- •Willing to fast a minimum of 8 hours before check-in.
- •Agree not to donate blood, plasma, platelets or any other blood components for 1 month after receiving study drug.
Exclusion Criteria
- •Any known chronic systemic viral infection (including a positive serological test for HIV, HBsAg or HCAb that indicates infection).
- •History of or current active tuberculosis (TB).
- •Any systemic infection or other systemic illness, including persistent cough, respiratory, or flu-like symptoms, in the previous 30 days before screening.
- •History of histoplasmosis, coccidioidomycosis, or similar opportunistic fungal infection.
- •Vaccination in the previous 30 days before screening.
- •History of, or clinically significant evidence of, bradycardia, syncope, or ECG abnormality or any other cardiovascular abnormality.
- •Resting heart rate (HR) during screening or baseline ECG fewer than 50 beats per minute (bpm).
- •History of seizures.
- •History of drug (including amphetamines, barbiturates, benzodiazepines, cocaine, opiates, phencyclidines, and cannabinoids) or alcohol abuse or addiction within the past 2 years or, if male, consumes more than 28 units of alcohol per week or, if female, consumes more than 21 units of alcohol per week (1 unit of alcohol equals 250 mL of beer, 100 mL of wine, or 25 mL of spirits).
- •Any history of abnormal pulmonary function (e.g., asthma or related respiratory illnesses).
Arms & Interventions
Q203
Q203 drug products (10mg and 100mg tablets)
Intervention: Q203
Placebo
Placebo tablets (same excipients used in Q203 drug products)
Intervention: Placebo
Outcomes
Primary Outcomes
Safety assessed through adverse events, vital signs, ECG, laboratory results, and telemetry monitoring
Time Frame: 7 days post dose
Secondary Outcomes
- Pharmacokinetic analysis: Area under the plasma concentration(predose and 1, 2, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 144, 216 and 312 hours postdose)
- Pharmacokinetic analysis: Time of maximum observed concentration(predose and 1, 2, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 144, 216 and 312 hours postdose)
- Pharmacokinetic analysis: Maximum observed plasma drug concentration(predose and 1, 2, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 144, 216 and 312 hours postdose)